Clinical Scorecard: CEBP-Altered B-ALL Across Ages: Two Distinct Transcriptomic Profiles
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: CEBP-Altered B-ALL Across Ages
Key Mechanisms
Two transcriptomic clusters were identified. Cluster A most closely aligned with CEBP/ZEB2 and featured concurrent ZEB2 p.H1038R and NRAS mutations; CDKN2A deletions were more frequent in this cluster. Cluster B most closely matched CEBPalt and was characterized by FLT3 mutations and frequent IKZF1 deletion.
Target Population
Patients or participants described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
Whole-transcriptome sequencing separated 24 CEBP-altered cases into two distinct transcriptomic clusters.
Cluster A most closely aligned with CEBP/ZEB2 and featured concurrent ZEB2 p.H1038R and NRAS mutations; CDKN2A deletions were significantly more frequent in this cluster.
Cluster B most closely matched CEBPalt and featured FLT3 mutations, frequent IKZF1 deletion, and a higher overall burden of karyotypic gains and losses.
The RIGHT workflow, together with examination of regions flanking CEBP genes, enabled detection of CEBP rearrangements in 19 of 24 cases through transcriptomic sequencing.
Both clusters included pediatric, AYA, and adult cases; the non-consecutive cohort showed no significant age-group or sex differences between clusters.
Guideline-Based Recommendations
Diagnosis
In this cohort, WTS with the RIGHT workflow and examination of regions flanking CEBP genes detected CEBP rearrangements in 19 of 24 cases and separated two transcriptomic profiles.
The authors describe IGH::CEBPE alone as an incomplete representation of the biology of CEBP-altered B-ALL.
The authors note that whole-genome sequencing and optical genome mapping remain important for detecting noncoding regulatory alterations and cryptic structural variants that may not produce detectable fusion transcripts.
Management
Monitoring & Follow-up
Risks
The authors note that analytical limitations in detecting IGH rearrangements may have contributed to missed recognition of some CEBP-altered disease.
The cohort was non-consecutive; the authors state that larger independent cohorts are needed to determine whether demographic differences reflect cohort composition or age-dependent variation in subtype prevalence.
Patient & Prescribing Data
The Australian cohort included pediatric, AYA, and adult patients with CEBP-altered B-ALL; 24 cases were analyzed by whole-transcriptome sequencing.
The article reports molecular and transcriptomic findings and does not provide treatment or prescribing data.
Clinical Best Practices
The reported clusters differed in cooperating molecular findings: Cluster A featured concurrent ZEB2 p.H1038R and NRAS mutations and more frequent CDKN2A deletions; Cluster B featured FLT3 mutations and frequent IKZF1 deletion.
The authors report that WTS can delineate the two transcriptomic profiles, while comprehensive genomic methods remain important for identifying noncoding and cryptic structural alterations.
Cluster B showed enrichment for pre-B I cells, whereas Cluster A showed enrichment for pre-B II Small or Immature B cells.
CAR T Vision aims to widen access to cell therapy by expanding community-based delivery, easing operational barriers, and building sustainable funding models
